Northwestern University

The State University of New York

The United States of America, As Represented by the Secretary, Department of Health and Human Services

The Research Foundation for the State University

Functional Genetics, Inc.

Carol Carter

Jonathan Leis

Stanley N Cohen

Lorna Ehrlich

Lorna Erlich

Nico Tjandra

Arthur Goff

Madeleine Davison

The present invention provides a method of inhibiting release of a virus from a cell, comprising contacting the cell with a compound that binds an ubiquitin E2 variant (UEV) domain of a cellular polypeptide, or fragment thereof, with an affinity sufficient to inhibit or disrupt the binding of the cellular polypeptide, or fragment thereof, to ubiquitin.

Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction

A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.

Methods and compounds to inhibit enveloped virus release

The present invention provides methods for identifying peptides in a mammalian. Tsg101 protein that binds to the PTAPP (SEQ ID NO: 3) motif or L domain of human immunodeficiency virus type I (HIV-1). Such peptides can be used to inhibit Tsg101-HIV Gag binding, and is therefore effective in reducing HIV particle production. The invention also provides the peptides identified by the method of the invention and to method of using such peptides for treating HIV infection.

Assay for TSG101 as inhibitors of HIV production

Growing community of inventors

Huntington, NY, United States of America

Carol Carter